Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12,404 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A quality-adjusted survival time without symptoms or toxicities analysis of glasdegib plus low-dose cytarabine versus low-dose cytarabine as initial therapy for acute myeloid leukemia in patients who are not considered candidates for intensive chemotherapy.
Solem CT, Bell TJ, Kwon Y, Cappelleri JC, Johnson C, Bhattacharyya H, Hoang CJ, Cortes JE. Solem CT, et al. Among authors: johnson c. Cancer. 2020 Oct 1;126(19):4315-4321. doi: 10.1002/cncr.33072. Epub 2020 Jul 22. Cancer. 2020. PMID: 32697335 Free PMC article. Clinical Trial.
Early switch/early discharge opportunities for hospitalized patients with methicillin resistant Staphylococcus aureus complicated skin and soft tissue infections: Saudi Arabia and United Arab Emirates.
Houfi AE, Thaqafi AA, Alenazi TH, Farahat F, Solem CT, Stephens JM, Johnson C, Macahilig C, Tang WY, Haider S. Houfi AE, et al. Among authors: johnson c. J Infect Public Health. 2020 Aug;13(8):1126-1133. doi: 10.1016/j.jiph.2020.03.018. Epub 2020 May 30. J Infect Public Health. 2020. PMID: 32482613 Free article.
Recovery From Opioid Use Disorder (OUD) After Monthly Long-acting Buprenorphine Treatment: 12-Month Longitudinal Outcomes From RECOVER, an Observational Study.
Ling W, Nadipelli VR, Aldridge AP, Ronquest NA, Solem CT, Chilcoat H, Albright V, Johnson C, Learned SM, Mehra V, Heidbreder C. Ling W, et al. Among authors: johnson c. J Addict Med. 2020 Sep/Oct;14(5):e233-e240. doi: 10.1097/ADM.0000000000000647. J Addict Med. 2020. PMID: 32187112 Free PMC article.
Early switch/early discharge opportunities for hospitalized patients with methicillin-resistant Staphylococcus aureus complicated skin and soft tissue infections in Brazil.
Furtado GH, Rocha J, Hayden R, Solem C, Macahilig C, Tang WY, Chambers R, Figueiredo MLN, Johnson C, Stephens J, Haider S. Furtado GH, et al. Among authors: johnson c. Braz J Infect Dis. 2019 Mar-Apr;23(2):86-94. doi: 10.1016/j.bjid.2019.04.003. Epub 2019 May 9. Braz J Infect Dis. 2019. PMID: 31078574 Free PMC article.
Real-world effectiveness of brentuximab vedotin versus physicians' choice chemotherapy in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplantation in the United Kingdom and Germany.
Zagadailov EA, Corman S, Chirikov V, Johnson C, Macahilig C, Seal B, Dalal MR, Bröckelmann PJ, Illidge T. Zagadailov EA, et al. Among authors: johnson c. Leuk Lymphoma. 2018 Jun;59(6):1413-1419. doi: 10.1080/10428194.2017.1382698. Epub 2017 Oct 18. Leuk Lymphoma. 2018. PMID: 29045163
Brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma who are Ineligible for autologous stem cell transplant: A Germany and United Kingdom retrospective study.
Bröckelmann PJ, Zagadailov EA, Corman SL, Chirikov V, Johnson C, Macahilig C, Seal B, Dalal MR, Illidge T. Bröckelmann PJ, et al. Among authors: johnson c. Eur J Haematol. 2017 Dec;99(6):553-558. doi: 10.1111/ejh.12973. Epub 2017 Oct 16. Eur J Haematol. 2017. PMID: 28949403
12,404 results
You have reached the last available page of results. Please see the User Guide for more information.